https://healthdev.ou.edu/medicine/academic-departments Parent Page: Academic Departments id: 21483 Active Page: Oncology Science id:27744
OU Seedthrower Statue

Department of Oncology Science

The Department of Oncology Science seeks to provide a research home to trainees, young investigators, and national/international leaders working in the areas of cancer prevention, diagnosis, treatment, and cure. We intend to achieve this through programs of excellence in research, education, outreach, and cost-effective patient care. The Department of Oncology Science is committed to facilitating interdisciplinary, collaborative, and innovative team-science to make OU Health Sciences Center a world-leader in translational cancer research.

Research Themes

Cancer Biology PhD Program Overview

The objectives of the Cancer Biology PhD Program are to mentor and train students in the field of cancer research. Housed within the Department of Oncology Science, our program trains students on research on new cancer diagnostic tools, molecular mechanisms, disease etiologies, cancer therapies, and quality of life measures. We are committed to facilitating interdisciplinary, collaborative, and innovative team-science to make OU Health Sciences Center a world-leader in translational cancer research. This coincides with the mission of the University of Oklahoma Health Sciences Center to educate students, residents, and other trainees in professional and graduate programs to become Oklahoma’s future team of healthcare leaders, clinicians, researchers, and educators.

Program Distinctions

The Cancer Biology PhD Program offers a unique emphasis on cancer-focused and translational research. Students benefit from our integration with the Graduate Program in Biomedical Sciences (GPiBS), which provides foundational training in core biomedical sciences. Through this structure, students have the opportunity to rotate through laboratories led by faculty from seven distinct research tracks, allowing them to explore diverse areas before selecting a research mentor. Application materials may be requested from gpibs@ouhsc.edu.

Upon successful completion of the GPiBS curriculum, students may formally join their chosen mentor’s laboratory to complete their doctoral training within the Cancer Biology PhD Program.

Direct Admission Option

In addition to the GPiBS pathway, students may also be admitted directly into the Cancer Biology PhD Program. Applicants with prior graduate coursework covering these core competencies from other institutions, may be eligible for credit transfer in accordance with the Graduate College Bulletin 4.6.1 - Transfer Credit for Doctoral Programs.

 

Students completing this program will receive a doctor of philosophy (PhD) degree in Cancer Biology.

 

As with all other graduate programs at OUHSC, the Cancer Biology PhD Program adheres to all guidelines and policies outlined by the Graduate College.


Financial Support

Graduate students stipends for the academic year 2025-2026 is $36,000 per year, plus tuition and health plan

If participating in GPiBS, tuition and stipend support for the first year of study will be granted through their office. During subsequent years, each student's Dissertation Advisor has responsibility for arranging this support.


For more information on the cancer biology graduate program, please contact:

Ms. Isabel Nierwinski
Administrative Manager
Department of Oncology Science
OU Health | Stephenson Cancer Center
isabel-nierwinski@ou.edu

Department of Oncology Seminar Series

The Department of Oncology Seminar Series is focused on current and emerging areas of cancer research. The seminars are organized with the goal of educating faculty, postdocs, students, and other trainees about the latest advancements in the field and facilitating interdisciplinary collaborations. 

Follow us on X and Instagram for upcoming seminar presentation announcements!

 @OncologyScience

@ouoncologyscience

 

News and Events

The Department of Oncology Science Welcomes Dr. Nydia Tejeda-Munoz to the Faculty!

The Department of Oncology Science Welcomes Dr. Nydia Tejeda-Munoz to the Faculty!


Published: Friday, August 11, 2023

Dr. Pankaj Singh, PhD, and the Department of Oncology Science is pleased to announce that Dr. Nydia Tejeda-Munoz has joined the department as an Assistant Professor. Dr. Tejeda-Munoz received a Ph.D. In Biomedical Sciences at the National Autonomous University of Mexico in 2016 with Cum Laude honors. For her postdoctoral studies, she was working with Professor Edward M. De Robertis, the Norman Sprague Professor of Biological Chemistry at the University of California, Los Angeles (UCLA). Dr. De Robertis is a world-renowned leader recognized for his discoveries in developmental biology using the Xenopus embryo as an experimental model, and is recognized for his discovery of Hox genes in vertebrates and the molecular nature of the Spemann organizer that controls the initial steps of embryonic differentiation.

Dr. Tejeda-Munoz's significant scientific contribution to date is that she discovered that the Wnt growth factor is a potent activator of macropinocytosis, also referred to as "cellular drinking" (Tejeda et al., 2019, PNAS; Albrecht*, Tejeda* et al., 2020, Cell Reports). This work helps understand how Wnt stimulates cellular growth in cancer cells. It explains earlier observations that Wnt increases the endocytosis of extracellular proteins digested in lysosomes (Albrecht et al., 2018, PNAS). Through her subsequent studies, she discovered that focal adhesion proteins are regulated by Wnt (Tejeda et al., 2022, PNAS; Tejeda et al., 2022, iScience). 

The loss of normal cell polarity and adhesion caused by Wnt signaling activation is a fundamental step for tumor progression and metastasis. The crosstalk between Wnt signaling and focal adhesions regulates adhesion, migration, and Wnt pathway component activities. Therefore, developing new strategies in Tejeda-Munoz's laboratory to restore adhesion and reduce invasive potential would be a breakthrough for cancer therapy. These original investigations on Wnt/lysosomes/macropinocytosis/focal adhesions may generate an innovative cancer progression, and treatments from unexpected directions, targeting endocytosis, macropinocytosis, lysosomes, and focal adhesions.